75 related articles for article (PubMed ID: 22569908)
1. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
[TBL] [Abstract][Full Text] [Related]
2. Platinum(IV) Complexes of
Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations.
Song Y; Suntharalingam K; Yeung JS; Royzen M; Lippard SJ
Bioconjug Chem; 2013 Oct; 24(10):1733-40. PubMed ID: 23957697
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Properties of Pt(II) and Pt(IV) Complexes with 2,2'-Dipyridylamine; the Comparative In Vitro Thereof.
Aghmasheh S; Ostad SN; Abedi A
Cell Biochem Biophys; 2020 Dec; 78(4):521-529. PubMed ID: 32851547
[TBL] [Abstract][Full Text] [Related]
5. Acetate-bridged platinum(III) complexes derived from cisplatin.
Wilson JJ; Lippard SJ
Inorg Chem; 2012 Sep; 51(18):9852-64. PubMed ID: 22946515
[TBL] [Abstract][Full Text] [Related]
6. Enhanced potency of a chloro-substituted polyaromatic platinum(II) complex and its platinum(IV) prodrug against lung cancer.
Baz J; Khoury A; Elias MG; Mansour N; Mehanna S; Hammoud O; Gordon CP; Taleb RI; Aldrich-Wright JR; Daher CF
Chem Biol Interact; 2024 Jan; 388():110834. PubMed ID: 38103879
[TBL] [Abstract][Full Text] [Related]
7. Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity.
Aher S; Zhu J; Bhagat P; Borse L; Liu X
Top Curr Chem (Cham); 2024 Feb; 382(1):6. PubMed ID: 38400859
[TBL] [Abstract][Full Text] [Related]
8. Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396859
[TBL] [Abstract][Full Text] [Related]
9. Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy.
Jayawardhana AMDS; Bhandari S; Kaspi-Kaneti AW; Kshetri M; Qiu Z; Cheline M; Shen H; Dunietz BD; Zheng YR
Dalton Trans; 2023 Aug; 52(31):10942-10950. PubMed ID: 37490033
[TBL] [Abstract][Full Text] [Related]
10. Chemical Imaging of Platinum-Based Drugs and their Metabolites.
Liu X; Hummon AB
Sci Rep; 2016 Dec; 6():38507. PubMed ID: 27917942
[TBL] [Abstract][Full Text] [Related]
11. The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs - an HPLC-ICP-MS study.
Theiner S; Grabarics M; Galvez L; Varbanov HP; Sommerfeld NS; Galanski MS; Keppler BK; Koellensperger G
Dalton Trans; 2018 Apr; 47(15):5252-5258. PubMed ID: 29560976
[TBL] [Abstract][Full Text] [Related]
12. Thermoresponsive carboplatin-releasing prodrugs.
McAdam AD; Batchelor LK; Romano-deGea J; Vasilyev D; Dyson PJ
J Inorg Biochem; 2024 May; 254():112505. PubMed ID: 38377623
[TBL] [Abstract][Full Text] [Related]
13. Joint forces of mass spectrometric techniques (ICP-MS and MALDI-TOF-MS) and fluorescence spectrometry in the study of platinum-based cytostatic drugs interactions with metallothionein MT2 and MT3.
Pavelicova K; Do T; Vejvodova M; Vaculovic T; Nowak K; Matczuk M; Wu S; Krężel A; Adam V; Vaculovicova M
Talanta; 2024 Jul; 274():125920. PubMed ID: 38574532
[TBL] [Abstract][Full Text] [Related]
14. Click-Capable Phenanthriplatin Derivatives as Tools to Study Pt(II)-Induced Nucleolar Stress.
O'Dowd PD; Guerrero AS; Alley KR; Pigg HC; O'Neill F; Meiller J; Hobbs C; Rodrigues DA; Twamley B; O'Sullivan F; DeRose VJ; Griffith DM
ACS Chem Biol; 2024 Apr; 19(4):875-885. PubMed ID: 38483263
[TBL] [Abstract][Full Text] [Related]
15. Oxidation of the Platinum(II) Anticancer Agent [Pt{(
Ojha R; Junk PC; Bond AM; Deacon GB
Molecules; 2023 Sep; 28(17):. PubMed ID: 37687231
[TBL] [Abstract][Full Text] [Related]
16. Novel design of dual-action Pt(IV) anticancer pro-drugs based on cisplatin and derivatives of the tyrosine kinase inhibitors imatinib and nilotinib.
Beirne DF; Farkaš B; Donati C; Gandin V; Rozas I; Velasco-Torrijos T; Montagner D
Dalton Trans; 2023 Oct; 52(39):14110-14122. PubMed ID: 37747105
[TBL] [Abstract][Full Text] [Related]
17. X-ray absorption spectroscopy of exemplary platinum porphyrin and corrole derivatives: metal-
Matson BD; Thomas KE; Alemayehu AB; Ghosh A; Sarangi R
RSC Adv; 2021 Sep; 11(51):32269-32274. PubMed ID: 35495496
[TBL] [Abstract][Full Text] [Related]
18. A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt
Kastner A; Poetsch I; Mayr J; Burda JV; Roller A; Heffeter P; Keppler BK; Kowol CR
Angew Chem Int Ed Engl; 2019 May; 58(22):7464-7469. PubMed ID: 30870571
[TBL] [Abstract][Full Text] [Related]
19. Platinum(IV)-azido monocarboxylato complexes are photocytotoxic under irradiation with visible light.
Shaili E; Romero MJ; Salassa L; Woods JA; Butler JS; Romero-Canelón I; Clarkson G; Habtemariam A; Sadler PJ; Farrer NJ
Dalton Trans; 2021 Aug; 50(30):10593-10607. PubMed ID: 34278398
[TBL] [Abstract][Full Text] [Related]
20. DNA-Intercalative Platinum Anticancer Complexes Photoactivated by Visible Light.
Shi H; Kasparkova J; Soulié C; Clarkson GJ; Imberti C; Novakova O; Paterson MJ; Brabec V; Sadler PJ
Chemistry; 2021 Jul; 27(41):10711-10716. PubMed ID: 34046954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
